Researchers studying anthrax knew they were onto something when they discovered an opponent the bacterium couldn’t outwit. Probing a bit deeper, they discovered this was because the attacker was interacting with something anthrax requires to survive: a carbohydrate in its cell wall. Now, in a study that has implications for the development of a new class of antibiotics, Rockefeller scientists report that they’ve determined the structure of an enzyme involved in the pathway responsible for building this essential carbohydrate.
The research stems from a collaboration between structural biologist C. Erec Stebbins and bacteriologist Vincent Fischetti, and is published online in
EMBO reports. The scientists not only describe the crystal structure of an enzyme involved in this vulnerable cell-wall pathway, they were able to use that structure to determine how the enzyme is regulated. And because the mammalian form of this enzyme is slightly different than the anthrax form, the researchers propose that it should be possible to inhibit its activity in bacteria without causing collateral damage to mammalian cells.
“These enzymes have a unique mode of regulation that’s actually going to tie into the idea of drug development,” says Stebbins, head of the Laboratory of Structural Microbiology. By creating a crystal structure of the enzyme with its substrate attached, he found that the enzyme’s activity is regulated by the very molecules it acts upon.
“So if we could bind a small molecule to the binding site in such a way that it doesn’t productively activate it, we could inhibit the activity of the molecule without inhibiting the same active site of mammalian enzymes,” Stebbins says. This, he hopes, would result in bacteria that are unable to build their cell walls and therefore would be unable to survive.
The anthrax bacterium has two copies of the gene responsible for producing this enzyme. To examine its potential as a drug target, Fischetti — head of the Laboratory of Bacterial Pathogenesis and Immunology — and his lab created a version of the bacterium with one of these genes knocked out. The resulting mutants grew much, much more slowly, Stebbins says, which tells them that if they could come up with an inhibitor, “it would probably hit these things hard.”
Also promising is that the same inhibitor site exists in a number of related bacteria, including those that cause staphylococcal infections and pneumonia. So if researchers could devise a drug that targets this site, it might be versatile enough to act against a range of bacteria. “It’s still in the very early stages,” Stebbins says, “but the structure gave us a very interesting idea for how we might tailor our drug search.”
Link:
http://www.nature.com/embor/journal/vaop/ncurrent/abs/7401154.html
Source: Rockefeller University
Related stories:
Biosensing nanodevice to revolutionize health screenings
One day soon a biosensing nanodevice developed by Arizona State University researcher Wayne Frasch may eliminate long lines at airport security checkpoints and revolutionize health screenings for diseases like anthrax, cancer and antibiotic resistant Staphylococcus aureus (MRSA).
Accelerator Systems Division keeps nation's brightest X-rays beaming
Argonne is home to the Advanced Photon Source, this hemisphere's most brilliant source of X-rays for scientific
research. The Accelerator Systems Division maintains the equipment to provide optimal X-ray quality with few interruptions to scientists. Researchers come from a variety of disciplines and from industry, academia and national and international laboratories. Research at this national facility, which is funded by the U.S. Department of Energy's Office of Basic Energy Sciences, ranges from materials science to structural biology.
Process used by microges to make greenhouse gases uncovered
Researchers here now have a picture of a key molecule that lets microbes produce carbon dioxide and methane – the two greenhouse gases associated with global warming.
Synthetic molecules emulate enzyme behavior for the first time
When chemists want to produce a lot of a substance -- such as a newly designed drug -- they often turn to catalysts, molecules that speed chemical reactions. Many jobs require highly specialized catalysts, and finding one in just the right shape to connect with certain molecules can be difficult. Natural catalysts, such as enzymes in the human body that help us digest food, get around this problem by shape-shifting to suit the task at hand.
Dividing cells find their middle by following a protein 'contour map'
Self-organization keeps schools of fish, flocks of birds and colonies of termites in sync. It’s also, according to new research, the way cells regulate the final stage of cell division. Scientists at Rockefeller University have shown that a protein-chemistry-based contour map, which helps individual proteins locate the center of their cell without direction from a “master organizer,” is key to ensuring accurate division during mitosis.
New research could lead to no scent, no sex for the Japanese beetle
No scent. No sex. If a male Japanese beetle is unable to detect the sex pheromone released by a female, he won't be able to locate her and reproduce.
SEX4, starch and phosphorylation
Some of the new molecular mechanisms and regulatory components in starch metabolism have been identified by Dr. Samuel Zeeman and his colleagues. Dr. Zeeman, of the Institute of Plant Sciences, ETH Zurich, in Switzerland, who is the 2007 recipient of the Charles Albert Shull Award, will be presenting this work at the opening Awards Symposium of the annual meeting of the American Society of Plant Biologists in Mérida, Mexico (June 27, 2:30 PM). Mutational and structural analyses by Dr. Zeeman and his colleagues have revealed that starch degradation in Arabidopsis leaves at night differs significantly from the versions traditionally described in textbooks. Specifically, mutations at the Starch Excess 4 (SEX4), Maltose Excess 1 (MEX1) and other loci produce plants unable to metabolize starch to a usable form.
Protein discovery may bolster antibiotic development
A team of scientists from Queen’s University has discovered the first ever three-dimensional structure of a protein family that may help in developing more effective antibiotics.
